Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with fungi and other pathogenic microbes
Among other things, disclosed herein are compositions and methods for using human-isolated or synthetic Alcaligenes faecalis, Bacillus altitudinis, Bacillus pumilus, Bacillus subtilis , or Janthinobacterium lividum . Compositions may improve skin health. Methods may include applying human-isolated or synthetic Alcaligenes faecalis, Bacillus altitudinis, Bacillus pumilus, Bacillus subtilis , or Janthinobacterium lividum over a host or host area, such as skin or mucosa to minimize the presence of one or more pathogenic microbes, maximize therapeutic effects of one or more additional therapeutics, and/or improve health of a host or host area.
1 . A composition comprising a probiotic, wherein the probiotic comprises human-isolated or synthetic Alcaligenes faecalis in an amount effective to treat a disease, disorder, or condition associated with a pathogenic microorganism, and a cryoprotectant, wherein the probiotic comprises a nucleic acid sequence at least 95% identical to that of SEQ ID NO: 6.
2 . The composition of claim 1 , formulated for topical application to a mammal for treating the disease, disorder, or condition, wherein the disease disorder, or condition is an infection.
3 . The composition of claim 2 , wherein the cryoprotectant results in greater efficacy, stability, and/or viability of the human-isolated or synthetic Alcaligenes faecalis as compared to a composition comprising the same human-isolated or synthetic Alcaligenes faecalis without the cryoprotectant.
4 . The composition of claim 1 , wherein the composition is frozen or lyophilized.
5 . The composition of claim 1 , wherein the cryoprotectant results in a greater percent recovery of the human-isolated or synthetic Alcaligenes faecalis after freezing or lyophilization as compared to a composition comprising the same human-isolated or synthetic Alcaligenes faecalis without the cryoprotectant.
6 . The composition of claim 1 , wherein the cryoprotectant comprises a disaccharide.
7 . The composition of claim 6 , wherein the disaccharide comprises trehalose.
8 . The composition of claim 7 , wherein the trehalose comprises D-trehalose, wherein the D-trehalose is about 2% to about 20% of the composition by weight.
9 . The composition of claim 1 , further comprising at least one additional isolated or synthetic microbe.
10 . The composition of claim 9 , wherein the additional isolated or synthetic microbe comprises a human-isolated or synthetic Bacillus altitudinis, Bacillus pumilus, Bacillus subtilis , or Janthinobacterium lividum.
11 . The composition of claim 9 , wherein the additional isolated or synthetic microbe comprises one or more microbes selected from Lactobacillus, Lactococcus, Cutibacterium , and Propionibacterium.
12 . The composition of claim 1 , further comprising a first additional isolated microbe and a second additional isolated microbe, wherein the first and second additional isolated microbes are independently selected from bacteria, virus, yeast, fungus, and any combination thereof.
13 . The composition of claim 1 , wherein:
a) the disease, disorder, or condition is associated with Malassezia, Staphylococcus, Candida , or Trichophyton ; and/or
b) the disease, disorder, or condition is Tinea barbae, Tinea capitis, Tinea corporis, Tinea cruris, Tinea pedis, Tinea versicolor , or onychomycosis or any combination thereof.
14 . The composition of claim 1 , further comprising a metabolite, cell lysate, or postbiotic from at least one species of human-isolated or synthetic bacteria selected from Alcaligenes faecalis, Bacillus altitudinis, Bacillus pumilus , and Bacillus subtilis.
15 . A probiotic composition comprising Alcaligenes faecalis and at least one cryoprotectant for use as a medicament, wherein the probiotic comprises a nucleic acid sequence at least 95% identical to that of SEQ ID NO: 6.
16 . The probiotic composition of claim 15 , for use in the treatment of a disease, disorder, or condition associated with at least one pathogenic microorganism.
17 . A kit comprising (i) at least one vial comprising the composition of claim 1 , and (ii) instructions.